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Abstract: Community acquired pneumonia (CAP) is the leading infectious cause of mortality worldwide 
with approximately 10% of patients hospitalized requiring intensive care unit (ICU) admission. The 
ability to predict clinical stability (CS) and treatment failure (TF) enables the clinician to alter antibiotics 
appropriately, facilitate a timely ICU admission, or arrange a suitable discharge. The detection of CS and TF 
can be difficult and changes in clinical signs may be subtle or delayed. Thus clinical scores and biomarkers 
are routinely used to identify severity and monitor clinical progression. The evidence, however, is vast and 
the definitive role of these systems is at times difficult to elucidate. The aim of this review is to analyse the 
current literature and to provide a rational and clinically focused view of the predictive utility of various 
systems used to identify CS and TF in CAP.
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Introduction
Pneumonia is the leading infectious cause of mortality 
worldwide (1). Community acquired pneumonia (CAP) is 
associated with a high mortality especially among the elderly 
and those with premorbid conditions (2,3). Approximately 
10% of patients hospitalized require intensive care unit 
(ICU) admission (4,5). In addition there are a significant 
proportion of patients discharged from hospital that are 
readmitted within 30 days (6). 
Early identification of severe disease and careful 
monitoring of treatment response is essential when managing 
patients. For this reason the concepts of clinical stability (CS) 
and treatment failure (TF) have been extensively studied. It 
follows that much research is focused on identifying useful 
surrogates for CS and TF. The evidence, however, is vast 
and the definitive role of biomarkers or clinical scores is 
at times difficult to elucidate. The aim of this review is to 
analyse the current literature and to provide a rational and 
clinically focused view of the predictive utility of various 
systems used to identify CS and TF in CAP.
Current concepts of CS and TF 
CS and TF are essential components of patient care. The 
ability to predict CS and TF enables the clinician to alter 
antibiotics appropriately imperative in the era of antibiotic 
resistance and antibiotic related complications. It also 
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facilitates a timely ICU admission and escalation in care, or 
alternatively an early appropriate discharge. A longer time 
to CS, or persistent TF is significantly associated with an 
excessive inflammatory response, poor clinical outcomes, 
a higher rate of pneumonia related complications, and 
prolonged length of stay and ICU admission (7-10). In 
addition, time to CS and presence of TF are considered 
crucial endpoints in the literature, similar to mortality 
outcomes (10-12). 
In an effort to standardize clinical endpoints in the 
literature and create useful clinical tools a number of 
definitions for CS exist. These include the American 
Thoracic Society and Infectious Disease Society of America 
(ATS 2001 and ATS/IDSA 2007) and Halms criteria 
(13,14). Using these criteria it has been demonstrated that 
the median time to CS in patients with CAP is between 
2–4 days (11,13). Interestingly, another important 
consideration is the actual sequence of clinical symptom 
and sign resolution. This varies greatly between patients 
and specific resolution patterns maybe associated with 
worse outcomes (15). In practice if CS is not achieved 
within 3 days, further investigation, treatment escalation 
or even ICU admission may be warranted. 
Conversely TF refers to ongoing infectious symptoms 
and signs while receiving treatment (4). Mortality increases 
several folds if TF is present (8). In the presence of TF 
within the first 3 days care providers should be concerned 
about a progression of primary pneumonia, and the need for 
treatment escalation or even ICU admission. Late failure may 
indicate pneumonia related complications or a super imposed 
infection. This differs from non-responding pneumonia in 
which there may not be a clinical deterioration (16). TF is 
subdivided in to early (within 72 hours of hospital admission) 
or late and can occur in up to 31% or 11% of inpatient 
admissions respectively (17). 
Systems to identify disease severity and monitor 
clinical progression
The detection of CS and TF can be difficult and changes in 
clinical signs may be subtle or delayed (4). Various clinical 
scores have been developed. 
Mortality scores include the Pneumonia Severity Index (PSI) 
and CURB-65 are validated for single use at the time of initial 
assessment. They are primarily designed to identify low risk 
patients suitable for outpatient management and are therefor 
less effective at identifying patients with severe disease (18,19). 
The PSI boasts better external validity when compared to 
the CURB 65. However, it consists of 20 variables and is 
therefor complicated to use in clinical practice. In addition it 
has not been validated for use on certain patient groups for 
example immunosuppressed patients and pregnant women 
(4,20). The CURB-65 (or simpler CRB-65) is easier to 
use consisting of just five parameters (confusion defined 
as mental test score ≤8, uraemia >7 mmol/L, respiratory 
rate ≥30 breaths/minute, blood pressure systolic <90 mmHg 
or diastolic ≤60 mmHg, age of 65 years or more). CURB-65 
has not been as extensively validated as the PSI. In addition, 
similar to the PSI, the CURB-65 score is not recommended 
for use in the immunosuppressed population (4). Both 
scores, in particular the CURB65, may underestimate 
mortality in the lower scoring patients (21). Both scores 
lack specificity when identifying patient with severe 
disease who require admission to ICU (19). The IDSA 
and ATS have issued revised based on the PSI and 
CURB-65 score for those with severe disease (4). IDSA/
ATS minor criteria has a high negative predictive value 
in the prediction of “emergency” CAP (patients that will 
require mechanical ventilation, vasopressors or who have 
a high risk of death) (22). However, CURB-65 has been 
shown to be superior to IDSA/ATS minor criteria in the 
prediction of mortality in patients with severe disease in 
a low mortality setting (hospital mortality 1.3%) (23). 
CS scores also exist most notably the Halms and ATS 
criteria. The advantage of these criteria is that they can 
be used to evaluate treatment response over time where 
normalization of various parameters equates to the 
achievement of CS (4,13). Both perform well, and strongly 
correlate to mortality and risk of complications. For 
example, in a large prospective observational study Akram 
et al. demonstrated an area under receiver operating 
characteristic curve (AUC) for 30-day mortality of 0.95 
and 0.94 for Halms and ATS respectively (24). Although 
Halms performs slightly better, ATS is easier to use with 
4 variables compared to the 7 components of the Halms. 
Both are widely used as end-points for CS in clinical 
trials (8,24,25). 
In summary, while all scores correlate well to mortality 
and risk of complications, simple and easier to use criteria 
are more likely to be applied in clinical practice. In addition, 
biomarker surrogates of host immune response are not 
included in these scores although it has been demonstrated 
that immune dysregulation correlates with a poorer 
prognosis (26). 
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Biomarkers 
Biomarkers as surrogates of disease severity 
Biomarkers are seen as an effective way of monitoring host 
response to infection. They are widely used to monitor 
disease severity and response to treatment in CAP. The 
search for the ideal molecular surrogate is ongoing. 
Although multiple biomarkers are undergoing rigorous 
investigation, C-reactive protein (CRP) and procalcitonin 
(PCT) remain the most robust and widely used (27,28). 
Among the pro-inflammatory cytokines, interleukin 6 (IL-6) 
has been of particular interest in the literature (29,30). 
CRP, PCT and IL-6 differ in the timing of response to 
a stimulus and half-life (Tables 1-3). CRP is predominantly 
synthesized in the liver in response to IL-6 induction of 
CRP mRNA (27,31). The single determinant of CRP 
level is the rate of synthesis in the liver in response to the 
inflammation intensity (27,32). In this way it is superior to 
more complex acute phase characteristics such as leukocytosis 
and fever (27). PCT is a 116 amino acid prohormone of 
calcitonin (31). In the event of a bacterial infection the 
CALC-1 gene is up regulated producing PCT in large 
amounts by macrophage and monocytic cells throughout 
the body especially the liver, lung and intestine (33). Some 
studies have demonstrated that it is a more sensitive 
and specific diagnostic marker of sepsis and CAP than 
CRP (34,35). The rise in PCT is more immediate when 
compared to CRP, due to cytokine like behavior. It is 
identified within 2–3 hours with a peak at 6 hours. The half-
life is 24 hours (31). Conversely CRP secretion begins at 
4–6 hours and peaks at 36–50 hours thereby potentially 
limiting its efficacy in predicting early TF (27,36). One 
conceivable advantage of IL-6 over CRP and PCT is an 
immediate response to infection (37,38). Another potential 
diagnostic advantage of IL-6 over PCT is that it is a 
more sensitive marker of localized infection, for example 
effusions (38) (Tables 1-3).
The role of biomarkers as a marker of severity and as 
a predictor of CS is well described (25,39,40). In a sizable 
prospective cohort study of 394 patients admitted to two 
large Spanish hospitals with CAP, 55.8% reached CS 
as defined by a modified version of the Halms criteria 
within 72 hours. As expected median levels of CRP, 
PCT, IL-6, IL-10 were significantly higher in patients 
Table 1 Characteristics of CRP
Secretion (hours from exposure)
Starts: 4–6
Peaks: 36
Factors that affect concentration levels
Increase
Inflammatory disease: rheumatoid arthritis, psoriatic arthritis, 
vasculitis, Crohns disease
Trauma: surgery, burns, fracture
Myocardial Infarction
Pancreatitis 
Fungal infection 
Malignancy: lymphoma, leukaemia
Decrease
Early infection 
Liver injury
Drugs: corticosteroid
CRP, C-reactive protein.
Table 2 Characteristics of PCT
Secretion (hours from exposure)
Starts: 2–3
Peaks: 6
Factors that affect concentration levels
Increase
Inflammatory disease
Trauma: surgery, burns, fracture
Myocardial infarction
Pancreatitis
Renal failure
Acute respiratory distress syndrome
Fungal infection
Drugs: antithymocyte globulin
Malignancy: medullary thyroid carcinoma, small-cell lung 
carcinoma
Decrease
Early infection
Localised infection
Subacute endocarditis
PCT, procalcitonin.
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who did not reach CS. Interestingly, although a small 
number of patients were used in the multivariate analysis, 
Menendez et al. successfully demonstrated that CRP 
was a significant independent predictor for the absence 
of severe complications slightly more than PCT (25). A 
larger prospective study of 570 patients admitted via the 
emergency department and acute medical unit in a large 
Scottish hospital demonstrated that CRP <100 mg/L 
on admission was significantly associated with reduced 
30-day mortality (OR 0.18, P=0.03), need for mechanical 
ventilation and/or inotropic support (OR 0.21, P=0.002) and 
complicated pneumonia (OR 0.05; P=0.003) (39). Similar 
to the Menendez study the negative predictive value of 
CRP for excluding severe complications (30 day mortality) 
in this investigation compared favorably to severity scores, 
this time to the CURB-65 and PSI. Other studies have 
demonstrated that Il-6 maybe a useful predictor of TF 
and mortality. In one hospitalized patients with elevated 
IL-6 were shown to have a higher risk of 30-day mortality 
with a sensitivity of 84% and specificity of 87%. In this 
prospective trial of 101 patients (24.8% mortality) there was 
good correlation between IL-6 levels and clinical severity 
scores (PSI, CURB 65 and MEWS). Interestingly, in this 
study comparator PCT levels did not reach significance (30). 
Signalling or functioning, are biomarkers good surrogates 
for clinical cure? 
Ideally biomarkers should be of high specificity and 
sensitivity, and useful for characterizing severity and 
monitoring response to treatment even in the absence 
of clinical signs (31,41). It is well described that patients 
with severe CAP who mount an excessive systemic pro 
inflammatory response are more likely to have a deleterious 
outcome. This immune response is complex however and 
biomarker dynamics may not be specific to the underlying 
disease and clinical status of the patient (26). When 
monitoring biomarker levels confounding factors should 
be taken in to consideration for example the effect of age, 
antibiotic pretreatment, corticosteroids, chronic hepatic 
disease, renal impairment and viral confection (10,42-45). 
For example, there is concern that the PCT response in 
patients with influenza, particularly influenza A (H1N1) 
PDM 09 may relate to the severity of viral pneumonitis 
as oppose to the bacterial co-infection (43,46). However, 
recently this was disputed when a study of 972 patients 
with H1N1 found that a cut off PCT of <0.29 ng/mL in a 
population with a 20% prevalence of community acquired 
respiratory coinfection has a high negative predictive value 
of 92%. PCT, therefor, appears to be effective at excluding 
co-infection in this group of patients (47). That said, it is 
important to interpret biomarker results cautiously and to 
correlate the results with clinical findings. 
Biomarkers have a number of limitations (Tables 1-3). 
Criticism of the role of CRP in diagnostics surrounds the 
delay in response to a clinical stimulus and poor specificity. 
It is elevated in a variety of pathology for example trauma, 
surgery, burns, and immunological mediated inflammatory 
diseases. In addition, caution should be taken when 
interpreting CRP levels in patients with hepatic injury 
and following corticosteroid use (48,49). PCT, in turn, is 
elevated in variety non-infectious conditions for example 
cirrhosis, pancreatitis, and mesenteric infarction, burns 
and aspiration pneumonitis (38,50,51). Furthermore 
the diagnostic and predictive power of PCT declines in 
patients with severe sepsis, and in localized infection for 
example in endocarditis and empyema (38,46,52). PCT 
levels should be interpreted with caution in impaired renal 
function (48). Studies differ as to appropriate negative 
cut-off point (38,53). IL-6, a relatively novel biomarker, 
is involved in a variety of haematopoietic, immune and 
inflammatory responses. It enhances T cell differentiation 
through the induction of IL-2. It acts as a pyrogen in the 
presence of infection or inflammation (54,55). Cytokine 
half-lives are short however and may decrease rapidly 
on clinical presentation. Cytokines also inherently lack 
specificity and are raised in a variety of inflammatory 
syndromes (29,56). Therefor overexpression of IL-6 is 
Table 3 Characteristics of IL-6 
Secretion (hours from exposure)
Starts: immediate
Peaks: 2–4
Factors that affect concentration levels
Increase
Inflammatory disease: rheumatoid arthritis, Crohns disease
Lymphoproliferative disease: Castleman’s disease
Malignancy: multiple myeloma, prostate carcinoma, ovarian 
carcinoma
Cardiac myxoma
Decrease
Late infection
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associated with a range of conditions including multiple 
myeloma, Castlemans disease and rheumatoid arthritis (57). 
Validated cut-off points for IL-6 are not yet defined.
The prevailing finding seems to be is that higher levels 
of CRP and other biomarkers are present in patients who 
develop shock, severe respiratory failure, or who are at high 
risk of death reflective of the inflammatory host response 
to infection (58,59). Menendez discovered that an initial 
CRP of >25 mg/dL was associated double mortality risk 
compared with other patients with lower CRP with the 
same initial PSI stratification score (58). Outcomes are 
not always unanimous in this respect, however, for the 
reasons outlined above. For example, some studies report 
low CRP in severe sepsis, suggesting that CRP may have 
a semi-protective role (60). This is mainly reflected in 
animal studies however Que et al. described a low admission 
CRP in patients with severe streptococcal pneumonia 
that was associated with an increased risk of death. This 
was a modest retrospective analysis of 77 patients with 
streptococcal pneumonia of whom 12 (15%) died. The 
results were significant (P=0.034), a CRP of <169.5 mg/L 
predicted mortality in these patients with a sensitivity and 
specificity of 75% and 72% respectively (61). 
Therefor it is important to appreciate that at times 
biomarker response is unpredictable. It is essential to 
interpret all results with caution and in the context of the 
changing clinical syndrome. 
Biomarker dynamics in severe disease and in treatment 
response 
Another noteworthy consideration is the subtleties of 
biomarker dynamics. A number of studies have demonstrated 
that the rate of CRP or PCT change correlates with response 
to treatment or, inversely, with risk of complications. 
CRP kinetics is slower than that of PCT. A failure to 
decline after 3–5 days of antibiotic treatment is highly 
suggestive of TF, and highlights the need for antibiotic 
modification and further investigation for complications 
or other missed diagnosis. For example, Chalmers et al. 
demonstrated that failure of surveillance CRP to fall 
by 50% or more at day 4 is associated with increased 
risk of 30-day mortality (OR 24.5; P=0.001), need for 
mechanical ventilation (OR 7.1; P=0.0001) and complicated 
pneumonia (OR 15.4, P=0.0001) (39). Similarly in another 
study the rate of CRP decline during the first 5 days of 
ICU admission in particular after day 2 was significantly 
associated with hospital mortality (OR =1.03, P<0.001). 
A patient with a daily decline in CRP of 10% per day has 
32% reduced risk of mortality when compared with a 
similar patient with no CRP decrease (28). A multicenter 
study that focused on the role of consecutive CRP 
measurements in predicting TF discovered that a decline 
of CRP <60% in 3 days or <90% in 7 days was associated 
with inappropriate empiric antibiotic treatment (62). 
Coelho et al. considered CRP ratios at days 3, 5 and 7 in 
relation to day 1 CRP concentration during the first week 
of admission to ICU. A ratio that was higher than 0.5 at day 
5 was associated with a fivefold increased risk of death in the 
ICU. Patients with no CRP decline over the first 7 days had 
significantly higher mortality (mortality of 43.2% compared 
to 9.5% in those with faster CRP response P=0.001) (63). 
Interestingly Menendez discovered that CRP at day 1 had 
a high negative predictive value for early TF in addition to 
late failure predictive ability (59). 
PCT conversely has more rapid dynamics and is useful 
therefor at identifying TF at an earlier stage (59). A study 
of 100 patients with CAP demonstrated that a PCT risk 
from day 1 to day 3 of ICU admission was independent 
risk factor for mortality (OR >4 ), while a day 3 PCT 
value of <0.95 ng/mL was associated with a 95% survival 
probability (64). Similarly another observational cohort 
study of ICU patients with sepsis (52% with pneumonia) 
determined that failure of PCT to decline by 30% between 
days 2 and 3 of treatment reflected the need for treatment 
modification (65). Martin-Loeches also discovered in a case 
control study (TF versus non TF patients) that PCT may 
be more valuable at discriminating failure than 1L-6 and 
CRP (66). A Danish study demonstrated that an increase in 
PCT is an early independent predictor of all cause mortality 
over 90 days follow up period and was superior to CRP and 
PCT (67). 
Biomarkers as a guide to treatment 
There has been a lot of interest in biomarker directed 
treatment strategies. Perhaps the most encouraging data 
surround the negative predictive value of PCT as a guide 
to antibiotic initiation and discontinuation. Multiple large 
studies have shown that following a PCT algorithm is 
associated with a reduction in antibiotic use in pneumonia 
without increasing risk of complications. PCT is effective in 
rationalizing antibiotics in patients with COPD and asthma 
requiring hospital admission (68,69).
In particular the ProREAL study group, through an 
observational multinational multicenter prospective study 
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demonstrated a successful reduction in antibiotic exposure 
from 7.4 to 5.9 days using 0.25 ng/mL as the recommended 
level for antibiotic consideration (70). Similar conclusions 
can be derived from a number of randomized controlled 
trials (71-74). The ProHOSP group also demonstrated 
a decline in antibiotic adverse effects with PCT guided 
antibiotic discontinuation (72). 
The PRORATA trial considered critically ill patients 
with a range of bacterial infections (approx. 70% 
pulmonary). Although PCT directed therapy reduced 
antibiotic exposure, there was no difference in length of 
ICU admission. In addition, there was a slightly higher 
mortality in the PCT group between days 29–60 although 
after correction for confounders this was not significantly 
different (75). A systematic review of PCT antibiotic 
algorithm RCTs found that there was no significant 
difference in mortality between PCT patients control 
patients (OR 0.91) (76). More recently, however, a large 
multicenter RCT (SAPS study) of critically ill patients 
with infection demonstrated a significant decrease in 
mortality at 28 days and 1 year when using PCT guided 
treatment compared to standard of care (74). Moreover, 
PCT may have a more powerful negative predictive value 
in identifying patients who need ICU admission when 
compared to CRP and cytokines including IL-6 (77). 
New discovery of molecules or paradigms
Novel biomarkers
The evidence for use of biomarkers is vast and ever 
evolving. Most research surrounds the use of PCT and 
CRP. An elevated cytokine level, especially IL-6, correlates 
with disease severity and maybe more predictive of an 
early clinical deterioration than older biomarkers (29,30). 
Other note worthy biomarkers include hormone surrogates 
[pro-adrenomedullin (ProADM), copeptin], markers of 
coagulation (D-dimer) among others (48,78-80). 
Severe CAP is associated with a median cytokine 
concentration that has been shown to be twice as 
high as that of non-severe CAP (2). Zobel et al. also 
confirmed that elevated IL-6 was a strong predictor 
of 30-day mortality, with the median concentration of 
IL-6 significantly higher in patients who had a severe 
CAP course (54.4 vs. 16.6 pg/mL, P<0.001) (29). Similarly 
Menendez et al. demonstrated in an earlier study that along 
with CRP, IL-6 was an independent predictor for 30-day 
mortality (58). Martin-Loeches et al. demonstrated that IL-6 
was superior to PCT, CRP, IL-1 and IL8 in the prediction 
of early TF on day 1. IL-6 also had a high predictive value 
for late TF also (66). Interestingly studies suggest that 
genetic variability in the production of pro-inflammatory 
cytokines, in particular higher production of TNF alpha, 
IL-6, or the anti-inflammatory IL-10 is associated with 
higher mortality in sepsis including CAP (81,82). A large 
ICU based observational study verified that an IL-6 174 GG 
genotype was associated with less ARDS, Septic shock and 
MODs disease in ICU patients with CAP (83). 
ProADM and copeptin are stable surrogates of sepsis 
induced stress hormones. ProADM is a fragment of the 
vasodilator and bacteriocidal hormone adrenomedullin, 
particularly elevated in sepsis (84-86). Copeptin, a 
precursor of arginine vasopressin is raised in a variety 
of diseases including congestive heart failure but levels 
correlate significantly with poor outcomes in sepsis and 
CAP (80,87-89). Pro-ADM and Copeptin have been 
shown to be strong predictors of early mortality and 
adverse outcomes, potentially more than PCT and CRP. A 
systematic review of 12 studies confirms that an increased 
MR proADM is associated with increased risk of short 
term mortality and that a combination of proADM and 
CURB-65 is associated with an improved predictive 
efficacy (90). A sizable Swiss study discovered that ProADM 
was strong predictor of TF including death with an AUC 
that was significantly higher than that of CRP but similar 
to PCT (91-93). Similarly Copeptin has been shown to be 
a useful marker of early mortality or ICU admission, more 
so than other biomarkers (89). A small study of 51 patients 
demonstrated that copeptin was a significant predictor 
of ICU admission or mortality within 7 days, however 
PCT and MR proADM were not significant predictors of 
early decline (94). In a larger study of almost 370 patients 
copeptin was a more significant predictor of mortality than 
PCT, CRP and leukocyte count (89). Similarly in a large 
study from the German CAPNETZ group of 1740 copeptin 
was significantly higher in non survivors over 28 days more 
so than PCT and CRP (95). 
Less favorable results surround the use of D Dimer, 
a product of fibrin degradation and a widely used, easily 
measured biomarker for thromboembolic disease. An 
elevated D Dimer level may be a non-specific finding in 
clinical practice (96). That said, D Dimer levels reflect 
the pathological role coagulation and fibrinolysis play 
in development acute lung injury. Levels increase in 
patients with severe CAP at high-risk mortality (97). 
For example, in an analysis of a subset of 147 patients 
Annals of Translational Medicine, Vol 5, No 22 November 2017 Page 7 of 11
© Annals of Translational Medicine. All rights reserved.   Ann Transl Med 2017;5(22):443atm.amegroups.com
from one RCT, an elevated D Dimer was associated with 
severe CAP, early TF and 30 days mortality. Levels were 
not significant for late TF (98). However, D Dimer does 
not appear improve the predictive scores such as the PSI 
and CURB 65 (97,98). 
Immunoscore
In sepsis, there is a complex interplay between host and 
pathogen in disease evolution. As highlighted by revised 
sepsis guidelines an important prognostic component 
of sepsis is the scale of inflammatory response, a factor 
that is neglected in existing pneumonia scores (26,99). 
Therefor various studies have focused on enhancing the 
predictive ability of predictive scores through the addition 
of biomarkers (24,58). 
Studies focusing on integrating CRP with existing clinical 
predication scores provide a new intriguing insight in to 
this time-honored biomarker (24,99). In a well-designed 
prospective study of 453 patients with CAP; the accuracy 
of predicting 30-day mortality through the use CRP, PCT 
and cytokines independently and in combination with the 
PSI and CURB65 scales was considered. The AUC of 
these prediction scales significantly increased following the 
addition of CRP (CURB-65 AUC increased from 0.82 to 
0.85 and PSI AUC increased from 0.8 to 0.85). Interestingly 
the additive role of PCT to the clinical prediction scores in 
this study did not reach clinical significance (58). In another 
study by Menendez et al., the addition of CRP to the 
modified Halms score, improved the AUC to predict the 
absence of severe complications after day 3 from 0.77 to 0.84 
(P=0.059) almost reaching significance. This increase in 
AUC was not reproduced on addition of PCT to the Halm 
score (25). The accuracy of the combined CRP-Halms 
score appears to improve with more complicated and severe 
disease (24,25). 
As with CRP, PCT is a promising adjunct to existing 
clinical prediction scores, and has a high negative 
predictive value for mortality when used in this way. In 
large multicentre study of patients with CAP diagnosed 
in the Emergency Department (n=1,651), patient’s with a 
PCT level of <0.1 ng/mL had a significantly lower 30-day 
mortality rate, even those high clinical risk score as defined 
by the PSI and CURB 65. Therefor adding PCT improved 
the score’s predictive ability (53). Similarly the CAPNETZ 
study group demonstrated that the combined use of CURB-
65 and PCT improved the prognostic accuracy compared 
with CURB-65 alone (AUC 0.83 vs. 0.79, P<0.01). The 
additional use of PCT using a threshold of <0.228 ng/mL 
was able to predict patients with a low risk of death within 
all CURB—65 groups (100). Similar results have been 
demonstrated in other studies, however in two studies by 
Menendez et al. CRP was superior to PCT at predicting 
severe complications and mortality when added to selected 
severity scores (25,58). 
There were comparable results more novel biomarkers. 
The addition of IL-6 to existing clinical prediction scores 
improves accuracy. Zobel et al. demonstrated that including 
IL-6 in to a statistical model enhanced the CRB score 
with an AUC 0.8 compared to AUC of 0.701. In this study 
there was more modest increase in the AUC of CRB-65 
with addition of IL-6 (29). Pro-ADM and copeptin have 
been shown to improve the prognostic accuracy of existing 
clinical prediction scores e.g., CURB 65 and PSI (90,91). 
For example, in one study the combined use of PSI and 
Copeptin improves the AUC than for PSI alone (0.75 to 
0.83) (94). Christ-Crain et al. similarly demonstrated that 
the addition of proADM to PSI increased the AUC from 
0.73 to 0.77 (91). 
Conclusions 
In severe CAP the inflammatory response is complex and 
poorly controlled (101). As the interrogation of various 
immune-modulatory therapies intensify, so will the search 
for an appropriate surrogate of severity and treatment 
response (102). It is essential to deliver early, targeted 
treatment, and to continually assess the patient for an 
appropriate clinical response. It is important to be aware of 
the advantages and limitations of all available clinical tools. 
This review provides a concise summary of this rapidly 
evolving area. Diagnostic and predictive utility is likely to 
improve with a combination of scores and biomarkers, or 
even a biomarker panel, particularly in severely ill patients 
(99). Going forward it is essential to interrogate the 
evidence by rigorously analyzing data from large multisite 
trials, in a diverse cohort of patients. 
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